2018 SHARK TANK
$50,000 FUNDING ANNOUNCEMENT

FUNDING DEADLINES
4/24/18 – Let Nikki Adams know if you plan to submit an investigator initiated trial/study to compete for the $50,000 awarded via the SHARK TANK session (nikki.adams@emory.edu).
5/3/18 – Send Nikki Adams completed slides of the proposed trial/study for judges to review.
5/11/18 – Someone from your team must pitch your idea at the Glenn Family Breast Center Retreat.

ELIGIBILITY
1. Research must be original, investigator-initiated and involve Emory Glenn Family Breast Center patients.
2. Therapeutic and non-therapeutic, prospective studies are eligible.
3. Someone from your team must pitch your idea at the 2018 Glenn Family Breast Center Retreat Friday, May 11th, for 5-10 minutes. Time will be allocated based on number of competing teams. The audience will be allowed to ask questions, and a non-partisan SHARK TANK panel of judges will provide feedback.
4. Engaging with a statistician is highly encouraged, if not mandatory, for trial design and power analysis.
5. To receive full funding, you must complete IRB approval for your study by March 2019.

Priority will be given to studies in the following areas:
Ductal Carcinoma In Situ (DCIS), Neoadjuvant treatment trials, Hormone refractory hormone receptor positive metastatic breast cancer, Plastics/Reconstruction, Breast Imaging, Health literacy/behavior, Local therapy studies - surgery or radiation, Disparities pertinent to our Atlanta community and the state of Georgia, Immune therapy/inflammation

EXCLUSION CRITERIA
1. Only prospective studies involving patients who are consented to participate are eligible.
2. Retrospective studies or studies accessing samples from tissue bank or path department only are NOT eligible.
3. All studies must be prospective and involve patients [either therapeutic or observational/non-therapeutic (biomarker or imagine) correlative studies].
4. Studies already enrolling patients are NOT eligible.

TIPS FOR SUCCESS
• The judges have expertise in trial/study development and research in cancer but not necessarily breast cancer. Therefore, you must make strong arguments in the following areas:
  o Why your proposed study/trial is pertinent and addresses a significant problem facing breast cancer patients
  o How your trial/study will be completed by accruing patients from the Glenn Family Breast Center in a 30-month period and reach endpoints within a 36-month period (FEASIBILITY)
• Multidisciplinary teams – statistician, MD, basic scientists, public health scientist, imager and/or pathologist often come up with the most innovative and scientifically sound proposals. Preference will be given to teams with a mix of junior, mid-level and senior investigators.
• Multidisciplinary teams who propose studies with high potential for publication, expansion into the cooperative groups or multi-institutional trials, and/or lead to extramural funding will be most competitive.